3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended March 31, 2021:
−Removed: Total Number of
+Added: The following table summarizes the activity, by month, during the three months ended June 30, 2021:
+Added: Period Total Number of
Shares or Units
−Removed: Purchased as Part
−Removed: Announced Plans
+Added: Purchased, which were also Part of the Publicly Announced Plans or Programs
Maximum Number
4 unchanged sentences
Purchased Under
−Removed: January 25,349 $ 3.23 25,349 $ 6,108,241
−Removed: February 33,325 3.41 33,325 5,994,725
−Removed: March 33,050 3.26 33,050 5,887,030
+Added: April 25,977 $ 3.03 $ 5,808,276
+Added: May 38,459 2.84 5,698,887
+Added: June 93,969 (1)
+Added: 3.16 5,402,064
Total 158,405
−Removed: 10.1 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between A.J.
−Removed: Kazimi and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.11 of the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 12, 2021
−Removed: 10.2 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Martian E.
−Removed: Cearnal and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.12 of the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 12, 2021
−Removed: 10.3 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Leo B.
−Removed: Pavliv and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.13 of the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 12, 2021
−Removed: 10.4 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between Michael P.
−Removed: Bonner and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.14 of the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 12, 2021
−Removed: 10.5 Employment Agreement, dated March 8, 2021, effective as of January 1, 2021, by and between James L.
−Removed: Herman and Cumberland Pharmaceuticals, Inc., incorporated herein by reference to Exhibit 10.15 of the Registrant’s Annual Report on Form 10-K (File No.
−Removed: 001-33637) as filed with the SEC on March 12, 2021
+Added: (1) Of this amount, 66,321 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
+Added: 10.1 Employment Agreement, dated May 14, 2021, effective as of May 17, 2021, by and between John Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.16 of the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-33637) as filed with the SEC on May 14, 2021 .
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: May 14, 2021 By:
−Removed: /s/ Michael Bonner
−Removed: Michael Bonner
+Added: August 13, 2021 By:
+Added: /s/ John Hamm
Chief Financial Officer and Duly Authorized Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.